Gabapentin can help trigeminal neuralgia, though it’s not considered a first-line treatment. A meta-analysis of clinical trials found that gabapentin was actually more effective than carbamazepine (the standard first-line drug) at reducing pain, while causing significantly fewer side effects. Despite this, current guidelines still classify gabapentin as an alternative treatment because the overall body of evidence remains smaller than what supports older medications.
How Gabapentin Compares to Standard Treatment
Carbamazepine and oxcarbazepine are the drugs most commonly prescribed first for trigeminal neuralgia. They have decades of clinical data behind them. But a systematic review published in Frontiers in Neurology, pooling data from multiple studies, found that patients taking gabapentin had roughly twice the odds of achieving effective pain relief compared to those on carbamazepine. Pain scores on a standard 10-point scale dropped slightly more in the gabapentin group as well.
The more striking difference was in side effects. Patients on gabapentin were about 72% less likely to experience adverse events than those on carbamazepine. That’s a meaningful gap, especially for a condition that often requires long-term medication. Carbamazepine is known for causing liver enzyme changes, low sodium levels, and blood cell count drops that require regular monitoring. Gabapentin doesn’t carry those same risks.
So why isn’t gabapentin prescribed first? The answer comes down to the quality and quantity of evidence. The studies comparing the two drugs are mostly smaller trials, and medical guidelines require large, rigorous trials before upgrading a drug’s recommendation. For now, gabapentin sits alongside pregabalin, topiramate, and levetiracetam as a promising alternative with fewer side effects but not yet enough evidence to displace the older drugs.
How Gabapentin Works on Nerve Pain
Trigeminal neuralgia involves misfiring signals along the trigeminal nerve, which runs from the brainstem to the face. Gabapentin reduces these signals by blocking a specific part of calcium channels on nerve cells. Calcium normally flows into nerve endings to trigger the release of chemical messengers that carry pain signals. By interfering with this process, gabapentin quiets overactive nerves in the spinal cord and brainstem, making them less likely to fire pain signals in response to normal stimuli like chewing, talking, or a light breeze on the face.
Gabapentin also appears to reduce the number of these calcium channel components that get shipped to nerve endings in the first place, which may explain why its effects build gradually rather than working immediately.
What to Expect When Starting Gabapentin
Gabapentin typically starts at a low dose, often 300 mg once daily in the evening, and is increased gradually over days or weeks. This slow ramp-up helps minimize side effects. The maintenance dose varies from person to person, but daily totals generally stay at or below 1,800 mg, split across multiple doses throughout the day.
Pain relief is not immediate. It can take up to a month to notice a meaningful difference, and if your dose is being raised slowly to manage side effects, that timeline stretches further. This is one of the more frustrating aspects of gabapentin for trigeminal neuralgia patients, since the pain can be severe and people understandably want fast results. Sticking with the gradual dose increase is important, though, because jumping to a high dose too quickly tends to cause more drowsiness and dizziness without speeding up relief.
Common Side Effects
The most frequently reported side effects in clinical trials are sleepiness (affecting roughly 15 to 20% of patients), dizziness (11 to 18%), unsteadiness when walking (about 13%), and fatigue (around 11%). These tend to be worst during the first week or two and often improve as your body adjusts. Taking the largest portion of your dose at bedtime can help manage the drowsiness.
Gabapentin is processed almost entirely by the kidneys, so people with reduced kidney function need lower doses. If you have kidney problems, your prescriber will adjust the amount based on how well your kidneys are filtering. This is routine and well-established, not a reason to avoid the drug, but it’s something your doctor needs to know about upfront.
Using Gabapentin Alongside Other Medications
For people whose pain doesn’t fully respond to gabapentin alone, combining it with another medication is a common next step. In a retrospective study of trigeminal neuralgia patients, those who lost their initial response to gabapentin sometimes regained relief when carbamazepine or phenytoin was added. Of patients who needed a second drug added to gabapentin, about half responded to the combination.
The reverse approach also works. In the same study, patients who were already on carbamazepine or phenytoin but still had pain saw improvement when gabapentin was added on top. More than half of those combination-therapy patients responded. This flexibility makes gabapentin useful both as a standalone option and as a supplement to other treatments, particularly for people who get partial relief from their current medication but need something more.
Where Gabapentin Fits in Your Treatment Plan
If you’ve tried carbamazepine or oxcarbazepine and couldn’t tolerate the side effects, gabapentin is one of the most reasonable next options. It’s also worth considering if you respond to carbamazepine but need additional pain control, since the two can be used together. Some doctors prescribe gabapentin as a first choice for older adults or people with other health conditions that make carbamazepine risky, since gabapentin’s side effect profile is considerably gentler.
The evidence increasingly suggests gabapentin deserves a larger role in trigeminal neuralgia treatment than guidelines currently give it. For many patients, it provides meaningful pain relief with fewer complications than the traditional first-line drugs. The gap between what the data shows and what the guidelines recommend is largely a matter of waiting for bigger, more definitive trials to catch up with what smaller studies have already demonstrated.